Solid Tumors:
Dose Escalation Only (Disease-Specific Expansion)

Solid tumors with PTEN or PIK3CB mutations
- Expansion: breast, prostate, other solid tumors
  ▼ 10131: Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

Solid tumors, no specific mutations
- Expansion: at least one pancreatic cancer cohort and possibly others
  10244: Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
- Expansion: recurrent small cell lung cancer
  ▼ 10070: Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
- Expansion: recurrent epithelial ovarian, fallopian tube, peritoneal cancer or recurrent TNBC
  ▼ 10031: A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
- Phase 2: advanced cholangiocarcinoma/ gallbladder carcinoma
  * 10276: A Phase II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Solid Tumors: Dose Escalation Only (Disease-Specific Expansion)

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 12, 2019